Moreover, determination of HOTAIRM1 level at diagnosis provided relevant prognostic information in a large series of IR-AML patients and allowed refinement of risk stratification based on common molecular markers. This evidence concerns the gene HOTAIRM1 and acute myeloid leukemia.